NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis $17.50 -0.20 (-1.13%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$17.52 +0.02 (+0.11%) As of 08/29/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Travere Therapeutics Stock (NASDAQ:TVTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Travere Therapeutics alerts:Sign Up Key Stats Today's Range$17.43▼$17.9450-Day Range$14.49▼$18.8252-Week Range$8.98▼$25.29Volume1.96 million shsAverage Volume1.75 million shsMarket Capitalization$1.56 billionP/E RatioN/ADividend YieldN/APrice Target$33.43Consensus RatingModerate Buy Company Overview Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Read More Travere Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreTVTX MarketRank™: Travere Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 583rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTravere Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Travere Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($1.40) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 23.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Travere Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.44% of the float of Travere Therapeutics has been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 17.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.44% of the float of Travere Therapeutics has been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 17.42%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment1.10 News SentimentTravere Therapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Travere Therapeutics this week, compared to 7 articles on an average week.Search Interest2 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,940.00 in company stock.Percentage Held by InsidersOnly 4.19% of the stock of Travere Therapeutics is held by insiders.Read more about Travere Therapeutics' insider trading history. Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVTX Stock News HeadlinesTravere Therapeutics stock jumps after FDA approves reduced monitoring for FILSPARIAugust 28, 2025 | au.investing.comTravere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA NephropathyAugust 27, 2025 | businesswire.comOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.September 1 at 2:00 AM | Crypto 101 Media (Ad)Canaccord Genuity Sticks to Its Buy Rating for Travere Therapeutics (TVTX)August 25, 2025 | theglobeandmail.comTravere Therapeutics (NASDAQ:TVTX) Cut to "Hold" at Wall Street ZenAugust 25, 2025 | americanbankingnews.comTravere Therapeutics Earnings Call Highlights FILSPARI SuccessAugust 23, 2025 | theglobeandmail.comCiti Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA CatalystsAugust 18, 2025 | msn.comTravere Therapeutics price target raised to $32 from $30 at WedbushAugust 8, 2025 | finance.yahoo.comSee More Headlines TVTX Stock Analysis - Frequently Asked Questions How have TVTX shares performed this year? Travere Therapeutics' stock was trading at $17.42 at the start of the year. Since then, TVTX stock has increased by 0.5% and is now trading at $17.50. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.14. The firm's revenue for the quarter was up 111.5% on a year-over-year basis. Read the conference call transcript. Who are Travere Therapeutics' major shareholders? Top institutional shareholders of Travere Therapeutics include Armistice Capital LLC (9.96%), Adage Capital Partners GP L.L.C. (3.12%), Emerald Advisers LLC (2.36%) and Geode Capital Management LLC (2.26%). Insiders that own company stock include Eric M Dube, Peter Heerma, William E Rote, Christopher R Cline, Jula Inrig, Jeffrey A Meckler, Elizabeth E Reed, Sandra Calvin, Gary A Lyons and Roy D Baynes. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Home Depot (HD), Walmart (WMT), Netflix (NFLX), Advanced Micro Devices (AMD) and Cisco Systems (CSCO). Company Calendar Last Earnings8/06/2025Today9/01/2025Next Earnings (Estimated)10/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TVTX CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees460Year FoundedN/APrice Target and Rating Average Price Target for Travere Therapeutics$33.43 High Price Target$47.00 Low Price Target$20.00 Potential Upside/Downside+91.0%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($2.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$321.55 million Net Margins-50.64% Pretax Margin-50.65% Return on Equity-717.68% Return on Assets-30.69% Debt Debt-to-Equity Ratio9.50 Current Ratio2.00 Quick Ratio1.98 Sales & Book Value Annual Sales$333.87 million Price / Sales4.67 Cash FlowN/A Price / Cash FlowN/A Book Value$0.76 per share Price / Book23.03Miscellaneous Outstanding Shares89,139,000Free Float85,520,000Market Cap$1.56 billion OptionableOptionable Beta0.78 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:TVTX) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.